Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer
Main Authors: | Ravi K. Anchoori, Rosie Jiang, Shiwen Peng, Ruey-shyang Soong, Aliyah Algethami, Michelle A. Rudek, Nicole Anders, Chien-Fu Hung, Xiang Chen, Xiuxiu Lu, Olumide Kayode, Marzena Dyba, Kylie J. Walters, Richard B. S. Roden |
---|---|
Format: | Article |
Language: | English |
Published: |
American Chemical Society
2018-09-01
|
Series: | ACS Omega |
Online Access: | http://dx.doi.org/10.1021/acsomega.8b01479 |
Similar Items
-
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
by: Ravi K Anchoori, et al.
Published: (2020-01-01) -
Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets
by: Xiuxiu Lu, et al.
Published: (2017-06-01) -
A High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells.
by: Xiuxiu Lu, et al.
Published: (2015-01-01) -
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling
by: Ruey-Shyang Soong, et al.
Published: (2020-05-01) -
Morse homology of RPn
by: Pöder, Sebastian
Published: (2013)